IL268008A - Ppargamma agonist for the treatment of huntington's disease - Google Patents
Ppargamma agonist for the treatment of huntington's diseaseInfo
- Publication number
- IL268008A IL268008A IL268008A IL26800819A IL268008A IL 268008 A IL268008 A IL 268008A IL 268008 A IL268008 A IL 268008A IL 26800819 A IL26800819 A IL 26800819A IL 268008 A IL268008 A IL 268008A
- Authority
- IL
- Israel
- Prior art keywords
- huntington
- disease
- treatment
- ppargamma agonist
- ppargamma
- Prior art date
Links
- 208000023105 Huntington disease Diseases 0.000 title 1
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762447741P | 2017-01-18 | 2017-01-18 | |
| PCT/US2018/014240 WO2018136635A1 (en) | 2017-01-18 | 2018-01-18 | Pparϒ agonist for the treatment of huntington's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL268008A true IL268008A (en) | 2019-09-26 |
Family
ID=62908392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL268008A IL268008A (en) | 2017-01-18 | 2019-07-11 | Ppargamma agonist for the treatment of huntington's disease |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20190350918A1 (enExample) |
| EP (1) | EP3570841A4 (enExample) |
| JP (1) | JP2020505448A (enExample) |
| KR (1) | KR20190122664A (enExample) |
| CN (1) | CN110461330A (enExample) |
| AU (1) | AU2018210165A1 (enExample) |
| BR (1) | BR112019014529A2 (enExample) |
| CA (1) | CA3050104A1 (enExample) |
| EA (1) | EA201991716A1 (enExample) |
| IL (1) | IL268008A (enExample) |
| MX (1) | MX2019008535A (enExample) |
| SG (1) | SG11201906644YA (enExample) |
| WO (1) | WO2018136635A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016144862A1 (en) | 2015-03-09 | 2016-09-15 | Intekrin Therapeutics, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
| KR20200036808A (ko) | 2017-04-03 | 2020-04-07 | 코히러스 바이오사이언시스, 인크. | 진행성 핵상 마비 치료를 위한 PPARγ 작용제 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8895541B2 (en) * | 2002-09-04 | 2014-11-25 | James A. Carnazza | Methods for inhibiting the development of huntington's disease |
| US20040224995A1 (en) * | 2003-05-09 | 2004-11-11 | University Of North Texas Health Science Center At Fort Worth | Neuroprotective effects of PPARy agonists against cellular oxidative insults |
| US7223761B2 (en) * | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
| DE10351744A1 (de) * | 2003-10-31 | 2005-06-16 | Schering Ag | Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel |
| AU2005295878A1 (en) * | 2004-10-13 | 2006-04-27 | University Of Connecticut | Cannabinergic lipid ligands |
| WO2009097996A1 (de) * | 2008-02-07 | 2009-08-13 | Sanofi-Aventis | Verwendung von substituierten phenylimidazolidinen zur herstellung von arzneimitteln zur behandlung des metabolischen syndroms |
| US20100087481A1 (en) * | 2008-10-03 | 2010-04-08 | Lee Kathleen M | Oral pharmaceutical formulations for antidiabetic compounds |
| US9028879B2 (en) * | 2009-07-01 | 2015-05-12 | Jds Therapeutics, Llc | Chromium complexes as enhancers of brain glucose transporters |
| WO2015095548A1 (en) * | 2013-12-20 | 2015-06-25 | Teva Pharmaceutical Industries Ltd. | Use of laquinimod to delay huntington's disease progression |
-
2018
- 2018-01-18 CN CN201880007571.4A patent/CN110461330A/zh active Pending
- 2018-01-18 SG SG11201906644YA patent/SG11201906644YA/en unknown
- 2018-01-18 US US16/476,979 patent/US20190350918A1/en not_active Abandoned
- 2018-01-18 JP JP2019559015A patent/JP2020505448A/ja active Pending
- 2018-01-18 AU AU2018210165A patent/AU2018210165A1/en not_active Abandoned
- 2018-01-18 EA EA201991716A patent/EA201991716A1/ru unknown
- 2018-01-18 EP EP18741523.7A patent/EP3570841A4/en not_active Withdrawn
- 2018-01-18 KR KR1020197023202A patent/KR20190122664A/ko not_active Ceased
- 2018-01-18 CA CA3050104A patent/CA3050104A1/en not_active Abandoned
- 2018-01-18 MX MX2019008535A patent/MX2019008535A/es unknown
- 2018-01-18 BR BR112019014529-0A patent/BR112019014529A2/pt not_active Application Discontinuation
- 2018-01-18 WO PCT/US2018/014240 patent/WO2018136635A1/en not_active Ceased
-
2019
- 2019-07-11 IL IL268008A patent/IL268008A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3570841A4 (en) | 2020-08-19 |
| JP2020505448A (ja) | 2020-02-20 |
| BR112019014529A2 (pt) | 2020-02-27 |
| EP3570841A1 (en) | 2019-11-27 |
| KR20190122664A (ko) | 2019-10-30 |
| MX2019008535A (es) | 2019-12-02 |
| SG11201906644YA (en) | 2019-08-27 |
| CA3050104A1 (en) | 2018-07-26 |
| US20190350918A1 (en) | 2019-11-21 |
| WO2018136635A1 (en) | 2018-07-26 |
| EA201991716A1 (ru) | 2020-02-04 |
| CN110461330A (zh) | 2019-11-15 |
| AU2018210165A1 (en) | 2019-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL271046B1 (en) | Compounds for the treatment of Huntington's disease | |
| IL281633A (en) | Methods for treating Huntington's disease | |
| IL277497A (en) | Compounds for the treatment of Huntington's disease | |
| EP3645121B8 (en) | Methods for treating huntington's disease | |
| IL265528A (en) | aav therapy for Huntington's disease | |
| ZA201608108B (en) | Huntington's disease therapeutic compounds | |
| EP3268086A4 (en) | Lsd for the treatment of alzheimer's disease | |
| EP3139966A4 (en) | Methods and compositions for treating huntington's disease | |
| IL263188B (en) | Treatment for Parkinson's disease | |
| GB201714027D0 (en) | Antisense oligonucleotides for the treatment of huntington's disease | |
| PL3285755T3 (pl) | Chlorowodorek kreatyny do leczenia choroby Huntingtona | |
| PL3697914T3 (pl) | Wektory do leczenia ataksji friedreicha | |
| GB201707501D0 (en) | New therapy 2 | |
| GB201707503D0 (en) | New Therapy 3 | |
| IL268008A (en) | Ppargamma agonist for the treatment of huntington's disease | |
| PL3804653T3 (pl) | Goniometr oczny | |
| EP3215222A4 (en) | Methods of treating huntington's disease using cysteamine compositions | |
| IL274536A (en) | Methods for prognosis or treatment of parkinson's disease | |
| SG11202101274XA (en) | Benzimidazole compounds and use thereof for treating alzheimer's disease or huntington's disease | |
| GB201820756D0 (en) | MJ's-vimana | |
| ZA201801945B (en) | Compositions and methods for the treatment of parkinson's disease | |
| ZA201807944B (en) | Treatment for parkinson's disease | |
| GB201811826D0 (en) | CAERvest 1 | |
| GB201808780D0 (en) | Lightpack 2 | |
| GB201805494D0 (en) | TidySqueeze 6 |